Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

33%(1 trials)

Phase Distribution

Ph phase_4

33%

Ph phase_1

33%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

Phase 4Post-market surveillance

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

Phase 41 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_2

Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes

NCT02617654

completedphase_4

Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

NCT03449654

completedphase_1

Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

NCT01373450

Clinical Trials (3)

Showing 3 of 3 trials

NCT02617654Phase 2

Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes

Completed

NCT03449654Phase 4

Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

Completed

NCT01373450Phase 1

Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3